# Predictive Safety Platform AI Partnership Model

**Version:** 1.0 | **Date:** 2026-02-06
**Owner:** Safety Research Team / Strategic Partnerships

---

## 1. Strategic Rationale

The frontier AI landscape evolves faster than any single pharmaceutical company can internalize. The platform adopts a **multi-model, partner-agnostic architecture** that treats AI model providers as interchangeable capability sources, evaluated continuously against safety-domain-specific benchmarks.

**Core principle:** When models improve, the platform improves --- automatically, without re-architecture.

---

## 2. Multi-Model Architecture

### 2.1 Model Portfolio

| Provider | Model | Primary Use Case | Endpoint |
|----------|-------|-----------------|----------|
| Anthropic | Claude Opus 4.5 | Mechanistic reasoning, safety narrative generation, regulatory document drafting | Managed Azure private endpoint |
| OpenAI | GPT 5.2 | Structured data extraction, literature NLP, multi-modal analysis | Managed Azure OpenAI Service |
| Google | Gemini 3 Ultra | Long-context analysis, genomics interpretation, cross-document synthesis | Managed GCP Vertex AI endpoint |

### 2.2 Routing Logic

The platform routes tasks to models based on empirical performance, not assumptions:

```
Task arrives
    |
    v
Task classifier (lightweight model) assigns task type
    |
    v
Lookup eval scores for task type across models
    |
    v
Route to highest-scoring model for that task type
    |
    v
If confidence < threshold: route to secondary model for verification
    |
    v
If models disagree on high-stakes output: escalate to human review
```

**Routing criteria:**
- Primary: Eval score on task-type-specific benchmark (updated monthly)
- Secondary: Latency (clinical alerts require <30s response)
- Tertiary: Cost per query (optimize for budget within performance constraints)
- Override: Regulatory requirements may mandate specific models for specific submission contexts

### 2.3 Automatic Capability Absorption

When a model provider releases an update:
1. New model version is deployed to secured evaluation environment.
2. Full platform eval suite runs automatically (see Evaluation Framework).
3. If new version meets or exceeds current version on all critical metrics: automatic promotion to production routing table.
4. If new version degrades on any critical metric: held for review by ML Engineering.
5. Routing weights updated. No code changes required.

This ensures the platform continuously absorbs improvements from the $10B+ annual R&D investment of major AI labs without internal re-development.

---

## 3. Custom Evaluations for Safety Prediction

### 3.1 Why Generic Benchmarks Are Insufficient

Standard AI benchmarks (MMLU, HumanEval, GPQA) do not measure capabilities relevant to pharmacovigilance. The platform maintains a custom evaluation suite targeting:

| Capability | Generic Benchmark Gap | Platform Eval |
|-----------|----------------------|----------|
| Cytokine cascade reasoning | Not tested | Multi-step immunological reasoning tasks |
| Temporal risk trajectory | Not tested | Time-series interpretation and prediction |
| Safety signal detection in noise | Not tested | Signal-to-noise discrimination in AE reports |
| Regulatory document comprehension | Partially tested | FDA/EMA guidance interpretation tasks |
| Mechanistic grounding | Not tested | Explanation validation against known pathways |
| Calibrated uncertainty | Not tested | Confidence calibration on safety predictions |
| Structured data extraction from CSRs | Not tested | Clinical study report parsing accuracy |
| Contradictory evidence handling | Not tested | Conflicting safety data synthesis |

### 3.2 Eval Suite Structure

The platform eval suite contains approximately 2,000 items across 8 capability domains, curated and validated by Safety Scientists and Clinical Pharmacologists.

**Eval item types:**
- **Factual recall:** Does the model know that IL-6 is a key driver of CRS?
- **Mechanistic reasoning:** Given a cytokine profile, can the model predict the downstream cascade?
- **Temporal interpretation:** Given a 72-hour cytokine trajectory, can the model identify the inflection point indicating escalation?
- **Clinical judgment:** Given a patient scenario, does the model's risk assessment align with expert consensus?
- **Calibration:** Are the model's stated confidence levels accurate across the probability range?
- **Adversarial robustness:** Does the model maintain accuracy when presented with misleading or incomplete data?

### 3.3 Eval Maintenance

- New items added quarterly from real clinical cases (anonymized and adjudicated).
- Items retired when they become trivial for all models (ceiling effect).
- Inter-rater reliability assessed annually (Safety Scientist panel).
- Eval results versioned and stored alongside model versions for full traceability.

---

## 4. Roadmap Influence

### 4.1 Shaping Partner Priorities

The organization, as a major enterprise customer, can influence AI provider roadmaps to prioritize capabilities relevant to pharmacovigilance:

| Priority Need | Current Gap | Engagement Strategy |
|--------------|------------|-------------------|
| Calibrated uncertainty quantification | Most models provide poorly calibrated confidence | Joint research collaboration, feature requests |
| Temporal reasoning over irregular time series | Limited native support | Benchmark contribution, use-case documentation |
| Medical ontology grounding (MedDRA, SNOMED) | Generic medical knowledge, not structured PV | Fine-tuning partnerships, terminology integration |
| Long-context clinical document analysis | Context windows sufficient but accuracy degrades | Eval contribution, performance feedback |
| Structured output reliability | JSON/schema adherence inconsistent | Schema validation feedback, regression reporting |
| Regulatory-grade audit trails | Not natively supported | Infrastructure requirements documentation |

### 4.2 Engagement Channels

| Channel | Cadence | Purpose |
|---------|---------|---------|
| Enterprise account teams | Monthly | Feature requests, roadmap previews, SLA discussions |
| Research partnerships | Quarterly | Joint publications, benchmark development, evaluation methodology |
| Early access programs | As available | Beta model evaluation against platform evals before GA |
| Industry consortia (PHUSE, TransCelerate) | Semi-annual | Pre-competitive standards for AI in safety |

---

## 5. Interpretability Requirements

### 5.1 Non-Negotiable Standard

Every platform prediction must be accompanied by an interpretation that a qualified Safety Scientist can evaluate. This is a regulatory requirement, not a preference.

### 5.2 Interpretability Stack

| Layer | Method | Output |
|-------|--------|--------|
| Feature attribution | SHAP values (model-agnostic) | Ranked list of features driving this specific prediction |
| Mechanistic mapping | Knowledge graph alignment | Which known biological pathways are implicated |
| Counterfactual | Nearest unlike neighbor analysis | What would need to change for risk classification to differ |
| Uncertainty decomposition | Aleatoric vs. epistemic separation | Is uncertainty from noisy data or limited training data |
| Natural language explanation | LLM-generated narrative (Claude/GPT) | Plain-language summary for clinical audience |

### 5.3 Validation of Interpretations

- Interpretability outputs validated by Safety Scientists (do explanations match clinical reasoning?).
- Periodic "interpretation audits" where blinded experts assess whether model explanations are plausible.
- Known failure mode: post-hoc explanations can be unfaithful to actual model reasoning. Mitigation: mechanistic constraints in model architecture, not just post-hoc SHAP.

---

## 6. Failure Transparency

### 6.1 Known Failure Modes

Platform documentation must explicitly enumerate known failure modes for each deployed model:

| Failure Mode | Detection Method | Mitigation |
|-------------|-----------------|------------|
| Hallucinated biological mechanisms | Mechanistic validation against curated knowledge graph | Hard constraint: explanations must map to known pathways |
| Overconfident predictions on out-of-distribution patients | Epistemic uncertainty monitoring, OOD detection | Confidence floor enforcement, human escalation |
| Systematic bias against demographic subgroups | Fairness metrics per subgroup (see Evaluation Framework) | Subgroup-specific calibration, bias auditing |
| Temporal distribution shift (new treatment protocols) | Drift detection on input feature distributions | Automated alerting, model revalidation trigger |
| Missing data sensitivity | Sensitivity analysis with simulated missingness | Explicit missing data indicators, imputation uncertainty |
| Adversarial inputs (data entry errors, corrupted feeds) | Input validation, anomaly detection | Reject predictions on out-of-range inputs |

### 6.2 Incident Response

- Model failures classified using standard severity framework (Critical / Major / Minor).
- Critical failures (false negative on Grade >= 4 event): immediate model quarantine, root cause analysis within 24 hours, corrective action plan within 72 hours.
- All incidents tracked in Platform Incident Register with full audit trail.
- Quarterly failure review with Steering Committee.

---

## 7. Evaluation Criteria and Benchmarking

### 7.1 Model Selection Criteria

| Criterion | Weight | Measurement |
|-----------|--------|-------------|
| Safety prediction accuracy | 30% | Platform eval suite composite score |
| Calibration quality | 20% | Expected calibration error across risk deciles |
| Interpretability fidelity | 15% | Expert-rated explanation quality |
| Latency (P95) | 10% | End-to-end response time |
| Security and compliance | 10% | SOC 2 Type II, data residency, encryption |
| Cost efficiency | 10% | Cost per 1000 predictions at target quality |
| Reliability (uptime SLA) | 5% | Contracted and observed availability |

### 7.2 Benchmarking Protocol

- **Frequency:** Monthly automated runs; full manual review quarterly.
- **Dataset:** Held-out evaluation set (never used in training or prompt engineering). Refreshed semi-annually.
- **Blinding:** Models evaluated by standardized harness; evaluators blinded to model identity during quality review.
- **Reporting:** Results published to internal model registry with full versioning. Accessible to Steering Committee and Regulatory Affairs.

### 7.3 Competitive Dynamics

The multi-model architecture creates healthy competition among providers:
- Providers see their relative performance (anonymized) and can target improvements.
- The platform benefits from rapid capability improvements driven by competitive market dynamics.
- No single-provider lock-in. Switching cost is limited to endpoint configuration.
- Contractual terms allow renegotiation based on demonstrated performance.
